Zota Health Care DuPont analysis

·UnclassifiedChart ›
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.93×0.93×0.98×0.89×1.23×
1.16×1.25×1.18×1.29×1.02×
−15.6%−11.9%−16.7%−6.9%−3.3%
0.69×0.69×0.88×0.93×0.94×
1.74×1.62×1.93×2.54×1.97×
−20.2%−15.4%−32.9%−18.8%−7.6%
−16.1%−16.1%−36.0%−16.9%−6.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ZOTA₹1,323.60

Zota Health Care LImited

· Unclassified
₹ CrorePeersMARINEBETATHEJOMcap ₹4,584 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×1.230.890.980.930.93
Interest Burden (Pretax/EBIT) ×1.021.291.181.251.16
EBIT Margin %-3.30-6.94-16.70-11.87-15.60
Asset Turnover ×0.940.930.880.690.69
Financial Leverage (Assets/Equity) ×1.972.541.931.621.74
ROE (5-step product, year-end total equity) %-7.63-18.76-32.95-15.42-20.20
ROE (owners' profit / average owners' equity) %-6.79-16.85-35.96-16.12-16.12
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.